Romiplostim

Nat Rev Drug Discov. 2008 Nov;7(11):887-8. doi: 10.1038/nrd2741.

Abstract

In August 2008, romiplostim (Nplate; Amgen), a thrombopoietin receptor agonist, was approved by the US FDA for the treatment of thrombocytopaenia in patients with chronic immune thrombocytopaenic purpura who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

Publication types

  • News

MeSH terms

  • Carrier Proteins / administration & dosage
  • Carrier Proteins / pharmacology
  • Carrier Proteins / therapeutic use*
  • Clinical Trials as Topic
  • Drug Approval
  • Humans
  • Receptors, Fc / administration & dosage
  • Receptors, Fc / therapeutic use*
  • Receptors, Thrombopoietin / agonists
  • Recombinant Fusion Proteins
  • Splenectomy
  • Thrombocytopenia / drug therapy
  • Thrombocytopenia / metabolism
  • Thrombocytopenia / surgery
  • Thrombopoietin
  • United States
  • United States Food and Drug Administration

Substances

  • Carrier Proteins
  • Receptors, Fc
  • Receptors, Thrombopoietin
  • Recombinant Fusion Proteins
  • MPL protein, human
  • Thrombopoietin
  • romiplostim